Dendrite Announces Grant under New Hire Authorization

Pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv),
as amended October 14, 2003, Dendrite International, Inc. (NASDAQ:
DRTE) today announced that stock options covering an aggregate of
100,000 shares of common stock were granted to Carl Cohen on June 28,
2006 in connection with his appointment as President, Marketing
Services, and stock options covering an aggregate of 25,000 shares
were granted to Ronald Pearce on June 26, 2006 in connection with his
appointment as Vice President and Corporate Controller. The Company
also announced that stock options covering an aggregate of 30,000
shares of common stock were granted to one non-executive officer
employee on April 24, 2006 and options covering an aggregate of 7,000
shares were granted to two non-executive officer employees on February
3, 2006.
   All such option grants were made under the Company's New Hire
Authorization as inducements to entering into employment with the
Company. All options granted include a ten-year duration and an
exercise price equal to the closing price of Dendrite's stock on the
business day immediately preceding the date of grant. The vesting
schedule for the options is as follows: (i) twenty-five percent (25%)
of the options shall first become exercisable on the first anniversary
of date of grant and (ii) the remaining seventy-five percent (75%)
shall become exercisable pro rata over the following three (3) year
period, on a monthly basis, commencing on the first anniversary of the
date of grant and ending on the fourth anniversary of the date of
grant.

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) provides
sales, marketing, clinical and compliance solutions for the global,
pharmaceutical industry. Dendrite has clients in more than 50
countries, including the world's top 20 pharmaceutical companies. For
more information, please visit www.dendrite.com.
   Note: Dendrite is a registered trademark of Dendrite
International, Inc.
   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.